Journal of Medicinal Chemistry · 2013 · 48 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryEnzymologyDiabetes ManagementDiabetes Mellitus BiochemistryEnzyme InhibitionNatural Product Drug DiscoveryNatural Product-based Drug DesignAldo-keto ReductasesAldose ChemistryAldose Reductase TargetsAntidiabetic Drug TherapyCarbohydrate-active EnzymesInhibitor Specificity
β-Glucogallin (BGG), a major component of the Emblica officinalis medicinal plant, is a potent and selective inhibitor of aldose reductase (AKR1B1). New linkages (ether/triazole/amide) were introduced via high yielding, efficient syntheses to replace the labile ester, and an original two-step (90%) preparation of BGG was developed. Inhibition of AKR1B1was assessed in vitro and using transgenic lens organ cultures, which identified the amide linked glucoside (BGA) as a stable, potent, and selective therapeutic lead toward the treatment of diabetic eye disease.
19
Biochemistry and molecular cell biology of diabetic complications
Michael Brownlee · Nature · 2001 · 9K citations
Donald S. Fong, Lloyd Paul Aiello, Thomas W. Gardner et al. · Diabetes Care · 2004 · 1.1K citations